Sorafenib angiogenesis inhibitors
systematic review meta-analysis network meta-analysis

Nexavar - BAY 43-9006 - sorafenib tosylate - BAY-545-9085 - BAY 545-9085 - 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate - sorafenib N-oxide - sorafenib

Select pdf

Filter

Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	death (overall survival)	progression or death (progression free survival PFS)
Group by... in first in second in third	Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Global trial result Main results All results All result tag NCT results	Numeric bar chart forest plot medians
advanced breast cancer (metastatic)
Baselga, 2012	sorafenib + capecitabine	capecitabine alone		HER-2 negative	Low risk of bias	suggesting
Schwartzberg, 2013 NCT	sorafenib + gemcitabine or capecitabine	gemcitabine or capecitabine alone		2nd line HER-2 negative	Exploratory	suggesting
Gradishar, 2013	sorafenib + paclitaxel	paclitaxel alone		1st line HER-2 negative	Low risk of bias	negative
lung cancer (metastatic)
Wakelee, 2012	sorafenib					-
Paz-Ares, 2012	sorafenib					-
Spigel, 2011	sorafenib and erlotinib	erlotinib				-
Scagliotti, 2010	sorafenib	placebo				-
renal-cell carcinoma (advanced)
Escudier, 2009	sorafenib	interferon alpha			Exploratory	negative
TARGET, 2007 NCT	sorafenib	placebo			Low risk of bias	suggesting
Ratain, 2006	sorafenib	placebo			Exploratory	-